Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
The Lancet Infectious Diseases (2022) - Comments
doi: 10.1016/s1473-3099(22)00420-0  issn: 1473-3099  pubmed: 35963274  issn: 1474-4457 

Raburn M Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Holly L Hammond, Lauren Baracco, James Logue, Matthew B Frieman, Gale Smith